SCHEMBL6573744

SCHEMBL6573744

COc1cc(C(=O)C(=O)N(C)C(Cc2ccccc2)C(=O)N(Cc2ncc[nH]2)C(CCc2ccccc2)CCc2ccccc2)cc(OC)c1OC

nearest known ligand 0.42

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.42
HTT P42858 2/20 0.42
GAA P10253 1/20 0.42
ALDH1A1 P00352 4/20 0.38
L3MBTL1 Q9Y468 2/20 0.37
LMNA P02545 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
KMT2A Q03164 2/20 0.37
MAPK1 P28482 1/20 0.36
FKBP1A P62942 5/20 0.36
LPAR1 Q92633 2/20 0.35
TP53 P04637 1/20 0.35
HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6573735 1.00 KDM4E (0.42) KDM4EHTTGAAALDH1A1L3MBTL1
SCHEMBL6573934 0.86 L3MBTL1 (0.40) KDM4EHTTALDH1A1L3MBTL1LMNA
SCHEMBL6573929 0.86 L3MBTL1 (0.40) KDM4EHTTALDH1A1L3MBTL1LMNA
SCHEMBL6572534 0.82 SLC2A4 (0.39) HTTALDH1A1L3MBTL1LMNASMN1; SMN2
Timcodar SCHEMBL3673444 0.82 L3MBTL1 (0.37) HTTALDH1A1L3MBTL1LMNASMN1; SMN2
SCHEMBL6570385 0.82 SLC2A4 (0.39) HTTALDH1A1L3MBTL1LMNASMN1; SMN2
SCHEMBL6570451 0.82 L3MBTL1 (0.37) HTTALDH1A1L3MBTL1LMNASMN1; SMN2
SCHEMBL6570448 0.82 L3MBTL1 (0.37) HTTALDH1A1L3MBTL1LMNASMN1; SMN2
Timcodar SCHEMBL1492143 0.82 L3MBTL1 (0.37) HTTALDH1A1L3MBTL1LMNASMN1; SMN2
SCHEMBL7177878 0.82 FKBP1A (0.40) HTTALDH1A1L3MBTL1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1420009-A2 Novel amino acid derivatives with improved multi-drug resistance activity Vertex Pharmaceuticals Incorporated (US) 2004-05-19 EP disclosed
EP-0797567-B1 NOVEL AMINO ACID DERIVATIVES WITH IMPROVED MULTI-DRUG RESISTANCE ACTIVITY VERTEX PHARMA (US) 2004-02-11 EP disclosed
EP-0946190-B1 METHODS AND COMPOSITIONS FOR STIMULATING NEURITE OUTGROWTH VERTEX PHARMA (US) 2003-09-24 EP disclosed
US-6284778-B1 NEUROTROPHIC AGENT VERTEX PHARMACEUTICALS INCORPORATED 2001-09-04 US disclosed
US-6172086-B1 TREATING PARKINSON*S DISEASE, ALZHIEMER*S DISEASE, AMYOTROPHIC LATERAL SCLEROSIS, MULTIPLE SCLEROSIS AND OTHER NERVOUS SYSTEM DISORDERS VERTEX PHARMACEUTICALS INCORPORATED 2001-01-09 US disclosed
EP-0946190-A1 METHODS AND COMPOSITIONS FOR STIMULATING NEURITE GROWTH USING COMPOUNDS WITH AFFINITY FOR FKBP12 IN COMBINATION WITH NEUROTROPHIC FACTORS Vertex Pharmaceuticals Incorporated (US) 1999-10-06 EP disclosed
US-5840736-A PEPTIDES FOR NERVE GROWTH VERTEX PHARMACEUTICALS INCORPORATED (US) 1998-11-24 US disclosed
WO-1998020891-A1 METHODS AND COMPOSITIONS FOR STIMULATING NEURITE GROWTH USING COMPOUNDS WITH AFFINITY FOR FKBP12 IN COMBINATION WITH NEUROTROPHIC FACTORS VERTEX PHARMACEUTICALS INCORPORATED (US) 1998-05-22 WO disclosed